Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS365 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INS365 Ophthalmic Solution | DRUG | - |
Inclusion Criteria: * have Non-Sjogren's associated dry eye disease with symptoms lasting greater than 6 months * had intermittent or regular artificial tear use within past 3 months Exclusion Criteria: * had LASIK surgery * had punctal occlusion or cauterization within last 3 months
INS365 is an investigational small molecule being developed for the treatment of keratoconjunctivitis sicca, commonly known as dry eye disease. It is formulated as an ophthalmic solution and is intended for use in patients with this condition. The drug is currently in Phase 3 clinical development.
INS365 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of INS365 for the treatment of dry eye disease.
INS365 is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating keratoconjunctivitis sicca, or dry eye disease.
INS365 has been studied in a Phase 3 clinical trial with the identifier NCT00037661. This completed trial, titled "Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye," enrolled 222 participants aged 18 years and older with keratoconjunctivitis sicca.
INS365 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of keratoconjunctivitis sicca, or dry eye disease. The drug has completed a clinical trial, but it has not yet received regulatory approval for marketing.